European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics.
Details
Serval ID
serval:BIB_89F413CA6F8C
Type
Article: article from journal or magazin.
Publication sub-type
Letter (letter): Communication to the publisher.
Collection
Publications
Institution
Title
European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics.
Journal
Journal of the European Academy of Dermatology and Venereology
ISSN
1468-3083 (Electronic)
ISSN-L
0926-9959
Publication state
Published
Issued date
05/2021
Peer-reviewed
Oui
Volume
35
Number
5
Pages
e308-e311
Language
english
Notes
Publication types: Letter
Publication Status: ppublish
Publication Status: ppublish
Abstract
The coronavirus disease 2019 (COVID-19) pandemic is caused by rapid spread of different strains of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The severity of infection ranges from mild, or even asymptomatic, to very severe. Signs and symptoms include fatigue, fever, exanthemas, upper respiratory illness, loss of smell and taste, pneumonia, severe acute respiratory syndrome, and multi-organ failure. Risk factors for a severe or lethal course include age, male gender, obesity, diabetes, cardiovascular disease, and immune suppression <sup>1</sup> .
Keywords
Adult, Biological Products, COVID-19, Dermatitis, Atopic/drug therapy, Humans, SARS-CoV-2, Vaccination
Pubmed
Web of science
Open Access
Yes
Create date
22/02/2021 10:57
Last modification date
30/05/2021 5:35